Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Multi-Center Study Evaluating the Safety and Efficacy of CD30-Directed Genetically Modified Autologous T Cells (CD30.CAR-T) in Adult and Pediatric Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

NCT04268706 is registered in ClinicalTrials.gov with Tessa Therapeutics as lead sponsor.

NCT NCT04268706
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04268706 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Multi-Center Study Evaluating the Safety and Efficacy of CD30-Directed Genetically Modified Autologous T Cells (CD30.CAR-T) in Adult and Pediatric Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Lead sponsor
Tessa Therapeutics
Phase
Phase 2
Overall status
Active, not recruiting
Start date
February 1, 2021
Completion date
March 31, 2037
Enrollment
97 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

hodgkin disease recurrent, hodgkin disease refractory, hodgkin disease, pediatric, hodgkin lymphoma, adult